http://www.mdrnainc.com () —
Marina Biotech, Inc. (NASDAQ: MRNA), formerly known as MDRNA, Inc., a
leading RNAi-based drug discovery and development company, announced
today that it will present at the Rodman & Renshaw 12th Annual
Healthcare Conference on Monday, September 13, 2010, at 3:15 p.m.
Eastern Time (12:15 p.m. Pacific Time) at the New York Palace Hotel in
New York City. J. Michael French, Marina Biotech President and Chief
Executive Officer, will present a corporate overview and business
update.
A live audio webcast will be available on the Event Calendar pages of
the Investors section of the Company's website at
http://www.marinabio.com (http://www.marinabio.com) . Please allow
time prior to the presentation to register and download any necessary
software. A replay of the presentation will be available on the
Investors section of the Marina Biotech website under Event Calendar
approximately one hour after the live presentation and will be
archived for three months.
About Marina Biotech, Inc.
Marina Biotech (formerly known as MDRNA, Inc.) is a biotechnology
company, focused on the development and commercialization of
therapeutic products based on RNA interference (RNAi). The Marina
Biotech pipeline currently includes a clinical program in Familial
Adenomatous Polyposis (a precancerous syndrome) and two preclinical
programs -- in hepatocellular carcinoma and bladder cancer. Marina
Biotech's goal is to improve human health through the development of
RNAi-based compounds and drug delivery technologies that together
provide superior therapeutic options for patients. Additional
information about Marina Biotech is available at
http://www.marinabio.com (http://www.marinabio.com) .